X
Qure.ai
Connect: •••
•••• ••••
•••
Key Metrics of Qure.ai
  • Market Cap
  • Total Equity Funding ₹1,007 Cr in 9 rounds
  • Latest Funding Round —, Grant (prize money) Jan 22, 2026
  • Post Money Valuation ₹2,261 Cr as on Mar 22, 2025
  • Annual Revenue ₹190 Cr
    ▲ 24% YoYas on Mar 31, 2025
  • EBITDA -₹65 Cr
    ▼ 88% YoYas on Mar 31, 2025
  • EBITDA Margin -34.13%
    ▼ 52% YoYas on Mar 31, 2025
  • Net Profit ₹90 Cr (Loss)
    ▼ 89% YoYas on Mar 31, 2025
  • Net Profit Margin -47.46%
    ▼ 53% YoYas on Mar 31, 2025
About the Company

Developer of artificial intelligence software for medical imaging diagnostic analysis. This technology integrates with existing radiology hardware to identify abnormalities...

Loading...
Price on BSE Volume

Funding Rounds

Total Rounds: 9 Qure.ai

S.No. Date Round Name Amount TTM Revenue Investors & Facilitators
1. Jan 22, 2026 Grant (prize money) - ₹300 Cr
Inst: Gates
2. Sep 23, 2024 Series D ₹543 Cr ₹172 Cr
Inst: 360 One, Merck Global Health Innovation Fund, Kae Capital, Novo Holdings, HealthQuad, TEAMFund, Lightspeed Venture Partners
Facil: DC Advisory
3. May 22, 2024 Series C ₹14 Cr ₹160 Cr
Inst: Merck Global Health Innovation Fund
4. Jun 28, 2023 Grant (prize money) - ₹107 Cr
Inst: C-CAMP
5. 2023 Grant (prize money) - ₹44 Cr
Inst: ACT Grants
6. Apr 29, 2022 Series C - ₹44 Cr
Inst: Merck, Merck Sharp & Dohme
7. Mar 29, 2022 Series C ₹303 Cr ₹39 Cr
Inst: MassMutual Ventures, HealthQuad, Novo Holdings, Merck, Akshat Greentech, TEAMFund
Facil: Lincoln International
8. Feb 23, 2022 Grant (prize money) ₹32 Cr ₹37 Cr
Inst: SBRI Healthcare
9. Feb 24, 2020 Series B ₹115 Cr ₹1.3 Cr
Inst: MassMutual Ventures, Redwood Trust, Peak XV Partners
Angel: Pranay, Rasesh, Don, Ajoy, Sankaranarayanan, Rajeswari, Parameswaran, Naushad, Sandeep, Natwar, Chiranjiv, Swetha, Gangaprasad, Bunty, Neema, Aparna, Satish, Reshma, Ammar, Hitiksha, Avinash, Divyaparvathy, Annu, John, Satish, Srikanth, Tarun, Ankit, Rohit, Sasank, Prashant

Financial Statements

Revenue - INR (Cr)

Net Profit/Loss - INR (Cr)

Select a year from the tabs

FY 24-25
FY 23-24
FY 22-23
FY 21-22
FY 20-21
FY 19-20
FY 18-19
FY 17-18
FY 16-17
Detailed Income StatementFY 24-25 (in Cr)
190.4
279.2
Total profit before exceptional items, extraordinary items and tax (88.8)
Total profit before tax (88.8)
1.6
Total profit (loss) for period from continuing operations (90.4)
Total profit (loss) for period (90.4)
Basic earning per equity share (0.0)
Diluted earnings per equity share (0.0)
Detailed Balance SheetFY 24-25 (in Cr)
553.5
553.5
Detailed Cash Flow StatementFY 24-25 (in Cr)
Net cash from / (used in) operating activities (96.7)
Net cash from / (used in) investing activities (225.8)
Net cash from / (used) in financing activities 289.8
Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes (32.6)
Effect of exchange rate changes on cash and cash equivalents 0.4
Net increase / (decrease) in cash and cash equivalents (32.3)
Cash and cash equivalents at the beginning of the year 67.7
Cash and cash equivalents at the end of the year 35.4
Detailed Income StatementFY 23-24 (in Cr)
154.0
200.7
Total profit before exceptional items, extraordinary items and tax (46.7)
Total profit before tax (46.7)
1.2
Total profit (loss) for period from continuing operations (47.9)
Total profit (loss) for period (47.9)
Basic earning per equity share (0.0)
Diluted earnings per equity share (0.0)
Detailed Balance SheetFY 23-24 (in Cr)
335.5
335.5
Detailed Cash Flow StatementFY 23-24 (in Cr)
Net cash from / (used in) operating activities (128.7)
Net cash from / (used in) investing activities 113.7
Net cash from / (used) in financing activities 0.5
Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes (14.5)
Effect of exchange rate changes on cash and cash equivalents (0.5)
Net increase / (decrease) in cash and cash equivalents (15.0)
Cash and cash equivalents at the beginning of the year 82.7
Cash and cash equivalents at the end of the year 67.7
Detailed Income StatementFY 22-23 (in Cr)
91.3
169.1
Total profit before exceptional items, extraordinary items and tax (77.8)
Total profit before tax (77.8)
0.1
Total profit (loss) for period from continuing operations (77.8)
Total profit (loss) for period (77.8)
Basic earning per equity share (0.0)
Diluted earnings per equity share (0.0)
Detailed Balance SheetFY 22-23 (in Cr)
364.6
364.6
Detailed Cash Flow StatementFY 22-23 (in Cr)
Net cash from / (used in) operating activities (60.0)
Net cash from / (used in) investing activities (173.1)
Net cash from / (used) in financing activities 299.4
Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes 66.3
Effect of exchange rate changes on cash and cash equivalents 0.4
Net increase / (decrease) in cash and cash equivalents 66.7
Cash and cash equivalents at the beginning of the year 15.9
Cash and cash equivalents at the end of the year 82.7
Detailed Income StatementFY 21-22 (in Cr)
39.3
62.8
Total profit before exceptional items, extraordinary items and tax (23.4)
Total profit before tax (23.4)
0.5
Total profit (loss) for period from continuing operations (24.0)
Total profit (loss) for period (24.0)
Basic earning per equity share (0.0)
Diluted earnings per equity share (0.0)
Detailed Balance SheetFY 21-22 (in Cr)
91.7
91.7
Detailed Cash Flow StatementFY 21-22 (in Cr)
Net cash from / (used in) operating activities (24.3)
Net cash from / (used in) investing activities (14.0)
Net cash from / (used) in financing activities 0.5
Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes (37.8)
Effect of exchange rate changes on cash and cash equivalents (0.0)
Net increase / (decrease) in cash and cash equivalents (37.9)
Cash and cash equivalents at the beginning of the year 53.8
Cash and cash equivalents at the end of the year 15.9
Detailed Income StatementFY 20-21 (in Cr)
12.4
32.3
Total profit before exceptional items, extraordinary items and tax (20.0)
Total profit before tax (20.0)
0.1
Total profit (loss) for period from continuing operations (20.1)
Total profit (loss) for period (20.1)
Basic earning per equity share (0.0)
Diluted earnings per equity share (0.0)
Detailed Balance SheetFY 20-21 (in Cr)
86.2
86.2
Detailed Cash Flow StatementFY 20-21 (in Cr)
Net cash from / (used in) operating activities (39.1)
Net cash from / (used in) investing activities (4.9)
Net cash from / (used) in financing activities 22.4
Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes (21.6)
Effect of exchange rate changes on cash and cash equivalents 0.1
Net increase / (decrease) in cash and cash equivalents (21.5)
Cash and cash equivalents at the beginning of the year 75.3
Cash and cash equivalents at the end of the year 53.8
Detailed Income StatementFY 19-20 (in Cr)
1.3
29.2
Total profit before exceptional items, extraordinary items and tax (27.9)
Total profit before tax (27.9)
0
Total profit (loss) for period from continuing operations (27.9)
Total profit (loss) for period (27.9)
Basic earning per equity share (0.0)
Diluted earnings per equity share (0.0)
Detailed Balance SheetFY 19-20 (in Cr)
99.0
99.0
Detailed Cash Flow StatementFY 19-20 (in Cr)
Net cash from / (used in) operating activities (7.6)
Net cash from / (used in) investing activities (10.6)
Net cash from / (used) in financing activities 93.5
Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes 75.3
Effect of exchange rate changes on cash and cash equivalents (0.4)
Net increase / (decrease) in cash and cash equivalents 74.9
Cash and cash equivalents at the beginning of the year 0.4
Cash and cash equivalents at the end of the year 75.3
Detailed Income StatementFY 18-19 (in Cr)
0.8
11.4
Total profit before exceptional items, extraordinary items and tax (10.6)
Total profit before tax (10.6)
Total tax expense 0
Total profit (loss) for period from continuing operations (10.6)
Total profit (loss) for period (10.6)
Detailed Balance SheetFY 18-19 (in Cr)
11.7
11.7
Detailed Cash Flow StatementFY 18-19 (in Cr)
Net cash from / (used in) operating activities (4.2)
Net cash from / (used in) investing activities (5.2)
Net cash from / (used) in financing activities 9.7
Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes 0.4
Net increase / (decrease) in cash and cash equivalents 0.4
Cash and cash equivalents at the beginning of the year 0.0
Cash and cash equivalents at the end of the year 0.4
Detailed Income StatementFY 17-18 (in Cr)
0.0
0.0
Total profit before exceptional items, extraordinary items and tax (0.0)
Total profit before tax (0.0)
0
Total profit (loss) for period from continuing operations (0.0)
Total profit (loss) for period (0.0)
Detailed Balance SheetFY 17-18 (in Cr)
16.2
16.2
Detailed Cash Flow StatementFY 17-18 (in Cr)
Net cash from / (used in) operating activities 1.2
Net cash from / (used in) investing activities (16.2)
Net cash from / (used) in financing activities 14.9
Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes (0.1)
Net increase / (decrease) in cash and cash equivalents (0.1)
Cash and cash equivalents at the beginning of the year 0.1
Cash and cash equivalents at the end of the year 0.0
Detailed Income StatementFY 16-17 (in Cr)
0
0.0
Profit/(Loss) before tax (0.0)
Total tax expense 0
Profit/(Loss) for the year (0.0)
Detailed Balance SheetFY 16-17 (in Cr)
0.1
0.1
Detailed Cash Flow StatementFY 16-17 (in Cr)
Cash flow from Operating activities 0
Net cash from/(used in) Operating activities 0
Cash flow from Investing activities 0
Net cash from/(used in) Investing activities 0
Cash flow from Financing activities 0.1
Net cash from/(used) in Financing activities 0.1
Net increase /(Decrease) in cash and cash equivalents before Effect rate changes 0.1
Effect of rate changes on cash and cash equivalents 0
Net increase /(Decrease) in cash and cash equivalents 0.1
Cash and cash equivalents at the beginning of the year 0
Cash and cash equivalents at the end of the year 0.1

Shareholding Pattern

As of Jan 14, 2026 • Qure.ai

Total Shares 0.05M

Top Shareholders

Shareholder Category Shares (Mn) % Holding
Aditya Jaiswal Other 0.05M 100.00%
Others

    Top Competitors

    Similar companies to Qure.ai

    AIdoc

    aidoc.com

    Oxipit

    oxipit.ai

    Subtle Medical

    subtlemedical.com

    Gleamer

    gleamer.ai

    ScreenPoint

    screenpoint-medical.com

    Brainomix

    brainomix.com

    Latest News

    Updates on Qure.ai
    Need help? Chat with us! WhatsApp